Articles

Aortic stenosis (AS) is one of the most common valvular disorders in older adults, with a prevalence of approximately 8 percent at age 85 (1).

Transcatheter valve replacement, especially transcatheter aortic valve implantation (TAVI), took center stage at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium this fall in...

October 15, 2010 – An investigational trial of Medtronic’s CoreValve transcatheter aortic valve has been approved by the U.S. Food and Drug Administration (FDA) today. The investigational device...

Transcatheter valve therapies were among the hottest topics at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) symposium and the key presentation was the very positive first release of...

The FDA’s approval of the Melody valve is widely viewed as a positive sign that may help other transcatheter valves to follow.

The FDA recently gave market clearance for Medtronic’s Melody Transcatheter Pulmonary Valve, the first transcatheter valve approved in the United States. The cardiology community expects this to...

In recent years, the U.S. cardiac device market has focused on dynamics in the drug-eluting stent (DES) segment – including events ranging from the 2006 BASKET-LATE trial that caused a tremendous...

September 11, 2009 – Abbott said yesterday it reached an $410 million agreement to purchase Evalve Inc., the global leader in the development of devices for minimally invasive repair of cardiac...

Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in interventional cardiology that will be presented during the Transcatheter...

The dividing line between the jobs performed by cardiac surgeons and interventionalists will become increasing blurred in the near future as transcatheter heart valves and PFO occluders replace...